South & Central America Cell and Gene Therapy Market

The South & Central America cell and gene therapy market was valued at US$ 67.28 million in 2023 and is projected to reach US$ 184.80 million by 2030; it is estimated to record a CAGR of 13.5% from 2023 to 2031.

Strategic Initiatives by Companies Boost South & Central America Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are as In March 2022, Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program—a suite of five multiplex CARs—to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist’s antibody libraries with Kriya’s proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya’s gene therapy technology. In January 2022, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies.

The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the South & Central America cell and gene therapy market during the forecast period.

South & Central America Cell and Gene Therapy Market Overview

Both profit and nonprofit organizations are propelling advanced medical product access and development in Brazil. In March 2024, for example, the Brazilian government's Fundação Oswaldo Cruz (Fiocruz), a foundation under the Ministry of Health in Brazil, partnered with Caring Cross, a 501(c)(3) nonprofit organization committed to advancing the development of cutting-edge medical treatments and facilitating access to all patients worldwide. Under this partnership, the government aims to establish local production of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for patients suffering from oncology, infectious, and genetic diseases in Brazil. These therapies also include CAR-T cell therapies for leukemia, lymphoma, and HIV infection. Brazil is attempting a novel collaboration between the Ministry of Health of Brazil and Fiocruz, the public health and research foundation. Therefore, a rise in the initiatives undertaken by profit and nonprofit organizations propel the market growth in the coming years.

South & Central America Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Cell and Gene Therapy Strategic Insights

Strategic insights for the South & Central America Cell and Gene Therapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Cell and Gene Therapy Report Scope

South & Central America Cell and Gene Therapy Regional Insights

The geographic scope of the South & Central America Cell and Gene Therapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Cell and Gene Therapy Market Segmentation 

The South & Central America cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the South & Central America cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the South & Central America cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the South & Central America cell and gene therapy market is bifurcated into pre commercial/ R and D manufacturing and commercial scale manufacturing. The pre commercial/ R and D manufacturing segment held a larger market share in 2023.

Based on end user, the South & Central America cell and gene therapy market is segmented into contract research

organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the South & Central America cell and gene therapy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International In, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, and Thermo Fisher Scientific Inc. are some of the leading companies operating in the South & Central America cell and gene therapy market.